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Antiretroviral Therapy Outcomes in Resource-Limited
Settings for HIV-Infected Children 5 Years of Age
WHAT’S KNOWN ON THIS SUBJECT: ART for children with HIV/
AIDS in resource-limited settings has been shown to be feasible,
but few data exist on ART outcomes in children 5 years of age.
WHAT THIS STUDY ADDS: ART for children 5 years of age is
feasible in resource-limited settings, with encouraging clinical
outcomes. Survival rates were reduced for children 12 months
of age, which emphasizes the need for early HIV diagnosis,
treatment, and adherence.
abstract
OBJECTIVE: We describe medium-term outcomes for young children
receiving antiretroviral therapy (ART) in resource-limited countries.
METHODS: Analyses were conducted on surveillance data for children
5 years of age receiving ART (initiated April 2002 to January 2008) in
48 HIV/AIDS treatment programs in Africa and Asia. Primary outcome
measures were probability of remaining in care, probability of devel-
oping World Health Organization stage 4 clinical events, rate of switch-
ing to second-line ART, and drug toxicity, compared at 6, 12, 24, and 36
months of ART.
RESULTS: Of3936children(90%inAfrica)initiatingART,9%were12
months, 50% were 12 to 35 months, and 41% were 36 to 59 months of
age. The median time of ART was 10.5 months. Probabilities of remain-
ing in care after 12, 24, and 36 months of ART were 0.85, 0.80, and 0.75,
respectively. Compared with children 36 to 59 months of age at ART
initiation, probabilities of remaining in care were signiﬁcantly lower
for children 12 months of age. Overall, 55% and 69% of deaths and
lossestofollow-upoccurredintheﬁrst3and6monthsofART,respec-
tively. Probabilities of developing stage 4 clinical events after 12, 24,
and 36 months of ART were 0.03, 0.06, and 0.09, respectively. Only 33
subjects (0.8%) switched to second-line regimens, and 151 (3.8%) ex-
perienced severe drug toxicities.
CONCLUSIONS: Large-scale ART for children 5 years of age in
resource-limited settings is feasible, with encouraging clinical out-
comes, but efforts should be increased to improve early HIV diagnosis
and treatment. Pediatrics 2010;125:e1039–e1047
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PEDIATRICS Volume 125, Number 5, May 2010 e1039Bytheendof2007,theJointUnitedNa-
tions Program on HIV/AIDS reported
that 2.1 million children 15 years of
age were living with HIV/AIDS through-
outtheworld,with90%insub-Saharan
Africa.1Despiterecentincreasesinan-
tiretroviral therapy (ART) in resource-
limited settings, coverage for children
has been signiﬁcantly less than that
for adults; of the 3 million people re-
ceiving ART by the end of 2007, only
6.6% (198000 people) were children.1
In most rural contexts in resource-
limited settings, services to prevent HIV
transmission from pregnant women to
their infants are not present, are not
accessed, or function poorly.2,3 Conse-
quently, many HIV-positive children be-
come infected perinatally or during
breastfeeding. Approximately 50% of
vertically infected children would die
before the age of 2 without treatment,
with mortality rates increasing to 75%
by 5 years of age.4,5 In the absence
of well-integrated maternal and child
health and HIV activities, many HIV-
infected children are neither diag-
nosed nor treated in time. The lack of
age- and context-appropriate diagnos-
tictools,smallnumbersoftrainedpro-
viders, and limited access to pediatric
drugformulationscontributetodelays
in treatment in these settings.
An increasing number of studies re-
port ART success for HIV-infected chil-
dren living in resource-limited set-
tings.6,7 However, most studies involve
relatively small numbers of children,
have median ages at ART initiation of
5 years, and provide little informa-
tiononclinicaloutcomes.6Fewstudies
have focused on outcomes in the criti-
cal ﬁrst years of life.
Doctors Without Borders/Me ´decins
Sans Frontieres (MSF) began provid-
ing ART in resource-limited settings in
2000. By the middle of 2008, MSF was
treating140000patientswithARTin
27 countries, with 10000 patients
being15yearsofageand4000be-
ing 5 years of age. This study details
ARToutcomesforHIV-infectedchildren
5 years of age, stratiﬁed according
to age groups, in MSF programs in
Africa and Asia.
METHODS
Setting and Participants
Children5yearsofagewhobeganto
receive ART in African or Asian MSF
programsbetweenApril2002andJan-
uary 2008 were eligible for the analy-
sis.Programswith5childrenreceiv-
ing ART were excluded. Age groups
were deﬁned according to age at ART
initiation,thatis,0to11,12to34,or35
to 59 months.
Information from 48 MSF programs
in 20 countries was included. African
programs included those in Benin,
Burkina Faso, Cameroon, Republic of
the Congo, Co ˆte d’Ivoire, Democratic
Republic of the Congo, Guinea, Kenya,
Liberia, Malawi, Mozambique, Nigeria,
Uganda, Zambia, and Zimbabwe. Asian
programs were those in Myanmar
(Burma), Cambodia, China, India, and
Laos.
All programs provided HIV counseling
and testing and free medical care in-
cluding ART, laboratory investigations,
and management of opportunistic in-
fections. For children 18 months of
age, HIV infection was diagnosed on
the basis of 2 positive rapid antibody
tests; for children 18 months of age,
HIV diagnosis was based on immuno-
logic and clinical criteria as recom-
mended by the World Health Organiza-
tion(WHO)orwasestablishedthrough
RNA or proviral DNA polymerase chain
reactiontestsusingdriedbloodspots,
when this technique was available.2
Daily cotrimoxazole prophylaxis was
prescribed routinely, according to
WHO criteria.2,8 All programs collected
patient monitoring data, in agreement
with the Ministry of Health, and oral
consent was obtained at treatment
initiation.
ART Eligibility and Regimens
Criteria for starting ART and ﬁrst-line
ART regimens were based on WHO rec-
ommendations.5,6 ART formulations
were mainly adult, generic stavudine-
based, ﬁxed-dose combination (FDC)
tablets, whole or cut in half if children
weighed 10 to 25 kg,9 with syrups for
thoseweighing10to14kg.Pediatric
FDC drugs were used as soon as they
were prequaliﬁed by the WHO (July
2007).
Children were clinically examined at
leastmonthlyduringtheﬁrst6months
of ART and then every 2 to 3 months
afterstabilizationontreatment.Adher-
ence support included designation of
1 caregiver, intensive pre-ART educa-
tion,andregulartreatmentadherence
sessions for both child and caregiver.
Where available, CD4 cell count mea-
surements were performed every 6 to
12 months, using FacsCount (BD,
Franklin Lakes, NJ), Partec (Partec,
Munster, Germany), or Dynabeads (In-
vitrogen,Carlsbad,CA).Becauseoflim-
ited availability in the ﬁeld and cost,
HIV viral loads were not systematically
determined.
WHO clinical staging used in the study
wasbasedon2006guidelines.5Clinical
eventsreportedwerebasedonclinical
diagnoses with or without biological
conﬁrmation, depending on the facili-
tiesavailable.Severeimmunosuppres-
sion was deﬁned according to 2006
WHO age-related thresholds, that is,
proportionsofCD4cellsof25%for
children12monthsofage,20%for
children 12 to 35 months of age, and
15% for children 36 to 59 months of
age.2
“ART-naive” was deﬁned as having no
previousARTexposure,includingexpo-
surethroughinterventionsforpreven-
tion of mother-to-child transmission.
Patients were considered to be receiv-
ing a second-line ART regimen if, af-
ter 6 months of treatment with a
nonnucleoside reverse transcriptase
e1040 SAUVAGEOT et al
 inhibitor-based, ﬁrst-line regimen, they
were switched to a protease inhibitor-
containing regimen with a concomi-
tant change of 1 nucleoside reverse
transcriptaseinhibitor.Severeantiret-
roviral drug toxicity was deﬁned as an
adverseeventrelatedtotheparticular
antiretroviral drug that resulted in
substitution with an alternative anti-
retroviral agent.
Data Collection
Data were collected and entered into
Fuchia monitoring software (Epicen-
ter, Paris, France), which is used in
most Doctors Without Borders HIV/
AIDS programs. Variables collected in-
cluded gender, age, previous and cur-
rent antiretroviral agents, visit dates,
WHO clinical stage, previous and cur-
rent clinical events, drug intolerance,
CD4 cell counts and CD4 cell pro-
portions, weight, and height.
Statistical Analyses
Probabilities of remaining in care were
calculated by using death and loss to
follow-up monitoring as combined end
points through the Kaplan-Meier meth-
od. Patients were considered lost to
follow-upmonitoringiftheymissedtheir
scheduledvisitby2months.Incidence
rates were expressed in child-years of
follow-up monitoring during ART for a
given time and population group. For in-
cidence calculations, the ﬁrst event
(WHO stage 4 clinical event, switch to
second-line treatment regimen, or drug
toxicity)occurringduringagivenperiod
was considered. Comparisons of pro-
portionswereperformedbyusingthe2
testandmediansbyusingKruskal-Wallis
tests. Analyses were performed with
Stata8.1(StataCorp,CollegeStation,TX).
RESULTS
Patient Characteristics at ART
Initiation
Between April 2002 and January 2008,
3936 HIV-infected children5 years of
age began ART in MSF programs; 3537
(89.8%)wereinAfricaand399(10.1%)
in Asia. A total of 335 children (8.5%)
12monthsofage,1971(50.1%)12to
35 months of age, and 1630 (41.4%) 36
to 59 months of age initiated ART.
NearlyallwerenaivetoART,themajor-
itywereclassiﬁedasbeinginWHOclin-
ical stage 3, most had severe immuno-
suppression, and many in Asia had
active tuberculosis (Table 1).
The main ART regimen for children 12
to 59 months of age was stavudine/
lamivudine/nevirapine. For the age
group of 12 months, zidovudine/
lamivudine/nevirapine was the most
prescribed regimen (Table 1).
Overall, baseline CD4 cell count data
wereavailablefor65%ofchildren.The
cohort of children without CD4 cell
count information was similar, in
terms of probability of remaining in
care, to the cohort with CD4 cell
count data at baseline (log rank test,
P.27). Larger proportions of children
12 months of age, compared with
children 36 to 59 months of age, had
severe immunosuppression at ART ini-
tiation in African (91.7% vs 74.1%;
P  .001) and Asian (88.9% vs 72.6%;
P  .05) programs (Table 1). Total ART
follow-up times were 3979 children-
years in Africa and 583 children-years
inAsia,withamedianfollow-uptimeof
10.5months(interquartilerange[IQR]:
3.7–20.6 months).
Probabilities of Remaining in Care
At the time of analysis, 2971 (75.5%)
children were still being monitored
in the program, 249 (6.3%) had died,
407 (10.3%) were lost to follow-up,
305 (7.8%) had transferred out, and
4 (0.10%) had unclear outcomes. Over-
all probabilities of survival were 0.93
(95% conﬁdence interval [CI]: 0.92–
0.94; n  1758), 0.92 (95% CI: 0.90–
0.93; n  862), and 0.90 (95% CI: 0.88–
0.91; n  304) after 12, 24, and
36 months of ART, respectively; proba-
bilities of remaining in care were 0.85
(95%CI:0.84–0.86),0.80(95%CI:0.78–
0.81), and 0.75 (95% CI: 0.73–0.77), re-
spectively. Compared with children 36
to 59 months of age at ART initiation,
probabilities of survival (log rank test,
P  .001) and remaining in care (log
rank test, P  .001) were signiﬁcantly
lower for children 12 months of age.
In addition, the probability of remain-
ing in care after 12 months of ART was
signiﬁcantly higher in Asian programs
(0.93 [95% CI: 0.89–0.95]; n  215)
thaninAfricanprograms(0.84[95%CI:
0.83–0.85]; n  1543; log rank test,
P  .001) (Fig 1).
Overall, 55% (n  353) of deaths and
losses to follow-up monitoring oc-
curred during the initial 3 months of
ART and 69% (n  442) occurred dur-
ing the initial 6 months. Findings were
not signiﬁcantly different when strati-
ﬁed according to age group or
continent.
Probabilities of Clinical Events
During ART
The probability of developing WHO
stage 4 clinical events in the ﬁrst
6 months of ART was 0.05 (95% CI:
0.04–0.05; n  2368; 141 events),
withseverebacterialinfections(36%),
cachexia (21%), and extrapulmonary
tuberculosis(18%)beingthemostfre-
quently reported diagnoses. The inci-
dences of WHO stage 4 clinical events
were highest in the ﬁrst 6 months of
ART in both Africa and Asia and in all
age groups (Table 2).
When only events that occurred after
6 months of ART were considered,
probabilities of developing WHO
stage 4 clinical events were 0.03 (95%
CI: 0.02–0.03; n  1714), 0.06 (95% CI:
0.05–0.07; n  804), and 0.09 (95% CI:
0.07–0.11;n278)after12,24,and36
months of ART, respectively. Again, the
most frequently reported clinical
events were severe bacterial infec-
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  tions (65.3%), cachexia (14.5%), and
extrapulmonary tuberculosis (8.9%).
Eventsoccurredafteramediantimeof
13.8 months (IQR: 8.7–21.7 months).
Second-Line ART Regimens
A total of 33 patients (0.8%) were
switchedtoasecond-lineARTregimen,
after a median time of 27.3 months
(IQR: 17.4–30.4 months). Most of these
switched patients were in Africa (n 
29 [87.9%]). Thirteen (39.4%) were 12
to 35 months of age at ART initiation,
and20(60.0%)were36to59monthsof
age. The overall incidence of switching
was 0.7 cases per 100 person-years
(95% CI: 0.5–1.0 cases per 100 person-
years), and rates did not differ signiﬁ-
cantly between continents or age
groups. The probability of remaining
on ﬁrst-line regimen after 24 months
of ART was 0.99 (95% CI: 0.98–0.99);
values were not signiﬁcantly different
when stratiﬁed according to continent
or age at ART initiation.
Drug Toxicity
A total of 151 children (3.8%) changed
1 of their ﬁrst-line antiretroviral
agents because of severe toxicity. The
probabilities of remaining free of se-
vere toxicity were 0.97 (95% CI: 0.96–
0.97; n  2391), 0.96 (95% CI:
0.95–0.97; n  1691), 0.95 (95% CI:
0.94–0.96; n  810), and 0.94 (95%
CI: 0.93–0.95) at 6, 12, 24, and 36
months of ART, respectively. The me-
dian time of ART at the time of antiret-
roviral drug change was 1.4 months
(IQR: 0.7–5.7 months).
In the ﬁrst 6 months of ART, toxicities
were more frequent in Asia than in
Africa (0.93 vs 0.97; log rank test,
P.001).Severetoxicitiesweresignif-
icantly more frequent with zidovudine
than with stavudine in African chil-
dren12to59monthsofage(P.001),
with a median weight of 8.1 kg (IQR:
7.2–9.5 kg). In Asia, toxicities tended
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A and B, Probabilities of remaining in care for children in African (A) and Asian (B) MSF HIV/AIDS programs, according to age at ART initiation. C and D,
Probabilities of survival for children in African (C) and Asian (D) MSF HIV/AIDS programs, according to age at ART initiation.
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 to be more frequent with nevirapine-
containing regimens (Table 3).
After 6 months, only 39 children (30 in
Africa and 9 in Asia) experienced a se-
vere drug-related adverse event, at a
median time of 16 months (IQR: 10–
26months).Nevirapinewasimplicated
in 17 cases (43.6%) and stavudine in
9 (23.1%).
DISCUSSION
In our study, the probability of remain-
ingincareafter3yearsofARTforchil-
dren 12 to 59 months of age was simi-
lar to that reported for adults and
older children from MSF and other Af-
rican cohorts in similar settings.6,10–16
In Asia, our reported survival rates for
children 12 to 59 months of age were
higher than those reported after 2
years of treatment for Thai and Cam-
bodianchildren,17,18aswellasadults.19
However, our results suggest that the
probability of remaining in care is sig-
niﬁcantly reduced for children 12
months of age, compared with those
who are older at ART initiation. In a
study of South African children, older
age at therapy initiation was associ-
ated with increased virological sup-
pression.11 This may be explained by
mortality rates for HIV-infected chil-
dren being highest in the ﬁrst year of
life,2 which suggests that those who
arestillalivewithouttreatmentat12
months of age have a survival advan-
tage and may have better treatment
outcomes. In addition, the relatively
oldermedianbaselineageof8months
atARTinitiationforthe12-monthage
group in our analysis might have af-
fected the subjects’ survival outcomes
adversely, because evidence showed
that young infants (3–6 months of
age) for whom ART was initiated ex-
perienced better outcomes. An Italian
study showed that infants for whom
ART was initiated at 6 months of
age experienced better virological,
immunologic, and clinical outcomes
than did those with initiation at 6
months of age, despite equivalent HIV
viral loads and CD4 cell counts.20
Data from the Children With HIV Early
Antiretroviral Therapy trial21 showed
that initiation of ART within the ﬁrst
12 weeks of life, rather than at the
TABLE 2 Incidence of WHO Stage 4 Clinical Events Among Children According to Age at ART Initiation
Africa Asia
12 mo 12–35 mo 36–59 mo 12 mo 12–35 mo 36–59 mo
Between initiation and 6 mo of ART
No. of child-years 92 664 556 9 60 86
No. of children with stage 4 events 10 60 49 2 10 12
No. of stage 4 events per child-year, estimate (95% CI) 10.9(5.3–20.2) 9.0(7.0–11.6) 8.8(6.7–11.7) 21.1(5.3–84.5) 16.6(8.9–30.8) 14.6 (8.5–25.2)
Between 6 and 12 mo of ART
No. of child-years 48 426 440 N/A 45 72
No. of children with stage 4 events 3 20 25 2 6
No. of stage 4 events per child-year, estimate (95% CI) 6.3(2.0–19.5) 4.7(3.0–7.3) 5.7(3.8–8.4) 4.5(1.1–17.8) 8.3(3.7–18.5)
After1yo fA R T
No. of child-years 43 712 854 N/A 87 168
No. of children with stage 4 events 2 29 30 2 5
No. of stage 4 events per child-year, estimate (95% CI) 4.7(1.2–18.8) 4.1(2.8–5.9) 3.5(2.5–5.0) 2.3(0.6–9.2) 3.0(1.2–7.1)
TABLE 3 Incidence of Antiretroviral Agent Toxicities During First 6 Months of Treatment According to Age at ART Initiation
Africa Asia
12 mo 12–35 mo 36–59 mo 12 mo 12–35 mo 36–59 mo
Stavudine toxicity
No. of events per 100 child-years, estimate (95% CI) 0 0.78(0.25–2.41) 0.21(0.03–1.49) N/A 2.18(0.31–15.5) 1.2(0.2–8.4)
No. of child-years 40 386 478 46 84
No. of events 0 3 1 1 1
Zidovudine toxicity
No. of events per 100 child-years, estimate (95% CI) 3.8(0.9–15.1) 4.3(2.4–7.5) 2.8(0.9–8.6) N/A N/A N/A
No. of child-years 53 282 108
No. of events 2 12 3
Nevirapine toxicity
No. of events per 100 child-years, estimate (95% CI) 0 1.9(1.1–3.4) 3.8(2.5–5.9) N/A 10.1(4.2–24.3) 8.3(3.7–18.5)
No. of child-years 84 617 523 50 72
No. of events 0 12 20 5 6
Efavirenz toxicity
No. of events per 100 child-years, estimate (95% CI) N/A 7.2(1.8–28.8) 0 N/A 0 0
No. of child-years 28 55 11 19
No. of events 2 0 0 0
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 previously WHO-recommended CD4
cell threshold of 20%,8 decreased the
riskofdeathby75%.Finally,thelarger
proportion of patients with severe im-
munosuppression in the 12-month
agegroupalsolikelycontributedtothe
worse outcomes with ART in this age
group.
Theshortintervalbetweenﬁrstconsul-
tation and ART initiation (1–2 months)
for infants suggests that failure to ini-
tiate ART in the ﬁrst few months of
life was inﬂuenced more by a delay
in HIV diagnosis than by delays in ART
initiation by clinicians. This may be re-
lated to several issues, including de-
layed presentation of HIV-exposed in-
fantstotheclinic,lackofawarenessof
HIV-related illness by caregivers and
careproviders,andlackofeasy-to-use
tools for HIV diagnosis in infants.22 Re-
inforcing the follow-up care of high-
risk infants born to HIV-positive moth-
ers especially needs to be addressed,
preferably through HIV-speciﬁc ser-
vices integrated into maternal and
child health clinics or primary health
care centers or family-friendly ser-
vices in HIV clinics.23 Integrating HIV
screening into WHO Expanded Programs
on Immunization in high-prevalence
settings may be an option to increase
HIV screening at very early ages.
The reduced probability of remaining
in care for the youngest children may
reﬂect poorer treatment adherence in
this age group. For the youngest chil-
dren, treatment success is strongly
linked to caregiver involvement and
capacity; sickness, education level,
and living conditions of caregivers,
residence in an orphanage, and inter-
ference with daily routines all inﬂu-
ence adherence.24–27 Furthermore,
childrenweighing10kgreceivedan-
tiretroviraldrugsinsyrupformulation
and dosages were weight dependent,
which often resulted in the use of
bulky, heavy bottles of antiretroviral
agents that posed logistic challenges
in terms of transport and storage by
the caregiver. In addition, administer-
ingdifferentquantitiesofdifferentsyr-
ups to children is complex and chal-
lenging, because of patient refusal
(taste), regurgitation, and hygiene is-
sues. In our experience, these issues
for caregivers may lead to (1) inaccu-
rate administration of antiretroviral
agents, increasing the risks of antiret-
roviral resistance,28 overdosing, or
toxicityandhenceincreasingmortality
rates, or (2) potential increases in the
risk of defaulting from care.
Fortunately, the situation has im-
proved somewhat with the recent
availability of quality-ensured FDCs of
3 antiretroviral drugs that can be
given to children weighing as little as
3 kg.29,30 However, development of
child-adapted formulations and FDCs
for other antiretroviral agents is
needed to provide more treatment op-
tions and easier, more-appropriate,
and more-accurate drug administra-
tion. This need is even more relevant
in light of recent WHO recommenda-
tions calling for protease inhibitor-
based ART for infants exposed to ne-
virapine through interventions for
prevention of mother-to-child trans-
mission.31 For better adherence, more
counselingtoolsadaptedtocaregivers
and young children need to be devel-
oped and the involvement of persons
living with HIV/AIDS at the community
level should be encouraged.
In our study, the probabilities of re-
maining in care were lower in African
programs than in Asian programs,
with 73% and 91% of patients, respec-
tively, still receiving ART after 3 years.
Favorable outcomes were observed
for children in Asian programs, de-
spite a higher level of baseline severe
immunosuppressionandahigherrate
of concurrent active tuberculosis,
compared with African programs.32
However, undiagnosed tuberculosis
might have been frequently present
before ART initiation in African co-
horts, leading to increased rates of
early death, compared with Asian co-
horts, through immune reconstitution
or lack of treatment. In addition, com-
pared with Asian programs, MSF Afri-
can programs generally are located in
areas with higher HIV prevalence and
less-developed health care infrastruc-
ture and have fewer resources and
qualiﬁed staff members.
The incidence of new WHO stage 4
clinical events decreased with time of
ART. It was highest during the ﬁrst
6 months, when infections present be-
fore ART initiation were likely to play a
role.33However,themostcommonclin-
icaldiagnosesreportedduringthispe-
riodweresimilartothosereportedaf-
ter6months.Littlehasbeenpublished
on the incidences and types of clinical
conditions among children receiving
ART in these settings. A study from
Kenya reported that the main causes of
death for children receiving ART were
pneumonia and diarrhea.34 In view of
our results, minimizing the incidence
of bacterial infections, tuberculosis,
and cachexia is important for children
duringtheﬁrstmonthsofART.Thisne-
cessitates improving the diagnosis
and treatment of tuberculosis before
ART initiation, through better clinical
assessment and improved diagnostic
tools for young children, which are
currently lacking. In addition, routine
prescriptionofandgoodadherenceto
cotrimoxazole prophylaxis, as well as
nutritional support, are important.
We reported a high probability of
young children continuing to receive
ﬁrst-line regimens for the ﬁrst 2 years
of ART, with low rates of switching to
second-line regimens. However, CD4
cell count measurements and clinical
evaluation have low sensitivity for de-
tecting virological failure.35,36 Increas-
ing access to virological monitoring to
allow earlier detection of treatment
failure may increase rates of switch-
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 ing in the future. Furthermore, if anti-
retroviral agents become less costly,
better adapted for children, and avail-
able in FDCs, this will offer clinicians
more options to change regimens ear-
lier if necessary.37
As observed in other studies, ART
for children seems to be well toler-
ated, with few severe drug toxicities
reported.18,38,39 Most intolerances oc-
curred during the ﬁrst 6 months of
treatment. In African programs, zido-
vudine was the antiretroviral drug
most commonly associated with se-
veretoxicity.Thismayberelatedtothe
increased risk of underlying anemia
attributable to coinfection with ma-
laria and underlying malnutrition. Se-
verenevirapine-andstavudine-related
toxicitieswerenotreportedoften,par-
ticularly for the youngest children, but
might have been underestimated be-
cause of underreporting.
Thisstudyhasseverallimitations.Firstly,
ourﬁndingsarebasedondatacompiled
from many African and Asian programs
in different environments, and case def-
initions, clinical practices, counseling
methods, and access to laboratory facil-
ities likely varied from one site to an-
other. Secondly, despite encouraging
clinical outcomes with ART, we are un-
able to comment on rates of HIV virolog-
ical suppression in the absence of viral
loadmonitoring.Finally,wewereunable
to assess the impact of adherence on
studied outcomes.
CONCLUSIONS
Ourstudyaddstotheexistingevidence
thatARTforchildren5yearsofageis
feasible,withencouragingclinicalout-
comes in resource-limited settings.
However, survival probabilities were
relatively reduced for children 12
months of age, which emphasizes the
need for increased efforts to improve
early HIV diagnosis and treatment in
this young age group.
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